Please login to the form below

Not currently logged in
Email:
Password:

Andrew Gengos joins ImmunoCellular as CEO

Will lead company as it initiates phase II trials investigating brain tumour vaccine

ImmunoCellular Andre GengosCancer specialist ImmunoCellular Therapeutics has appointed Andrew Gengos as president and CEO.

Gengos joins from Neuraltus Pharmaceuticals, where he also served as president and CEO, and becomes the permanent replacement for Dr Manish Singh who left the company in August 2012 to "pursue other opportunities".

Since August, ImmunoCellular's founder and chief scientific officer Dr John Yo has served as interim CEO.

Gengos joins at an important time for ImmunoCellular, with the company having recently commenced a phase II trial investigating its lead product candidate ICT-107, a potential cell-based vaccine for glioblastoma brain tumours.

ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

“Joining ImmunoCellular is an extraordinary opportunity to help build a leading biopharmaceutical company with the potential to transform the treatment of cancer,” said Gengos. “I believe that the company's immunotherapy platform that targets both cancer cells and cancer stem cells represents a promising and innovative medical breakthrough.”

Prior to joining Neuraltus spent more than seven years at Amgen, holding such positions as VP, strategy and corporate development.

He has also spent time at Dynavax Technologies, Chiron Corporation and McKinsey & Company.

5th December 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics